Yuflyma Purple Book BLA 761219
- BLA number
- 761219
- Proprietary names
- Yuflyma
- Proper names
- adalimumab-aaty
- Applicant
- CELLTRION, Inc.
- Center
- CDER
- First observed release
- 2023-06-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Yuflyma | adalimumab-aaty | 351(k) Interchangeable | 40MG/0.4ML | Injection | Subcutaneous | Autoinjector | Rx | Licensed | 2023-05-23 | |
| 002 | Yuflyma | adalimumab-aaty | 351(k) Interchangeable | 40MG/0.4ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2023-05-23 | |
| 003 | Yuflyma | adalimumab-aaty | 351(k) Interchangeable | 80MG/0.8ML | Injection | Subcutaneous | Autoinjector | Rx | Licensed | 2023-09-29 | |
| 004 | Yuflyma | adalimumab-aaty | 351(k) Interchangeable | 80MG/0.8ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2023-09-29 | |
| 005 | Yuflyma | adalimumab-aaty | 351(k) Interchangeable | 20MG/0.2ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2023-09-29 | |
Reference Biological Product#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 125057 | Humira | adalimumab | 351(a) | Rx | 2026-06-01 |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2025-05-01 | U | 001 | Yuflyma | 351(k) Interchangeable | Rx | CELLTRION, Inc. |
| 2025-05-01 | U | 002 | Yuflyma | 351(k) Interchangeable | Rx | CELLTRION, Inc. |
| 2025-05-01 | U | 003 | Yuflyma | 351(k) Interchangeable | Rx | CELLTRION, Inc. |
| 2025-04-01 | U | 004 | Yuflyma | 351(k) Interchangeable | Rx | CELLTRION, Inc. |
| 2025-04-01 | U | 005 | Yuflyma | 351(k) Interchangeable | Rx | CELLTRION, Inc. |
| 2023-10-01 | N | 003 | Yuflyma | 351(k) Biosimilar | Rx | CELLTRION, Inc. |
| 2023-10-01 | N | 004 | Yuflyma | 351(k) Biosimilar | Rx | CELLTRION, Inc. |
| 2023-10-01 | N | 005 | Yuflyma | 351(k) Biosimilar | Rx | CELLTRION, Inc. |
| 2023-06-01 | N | 001 | Yuflyma | 351(k) Biosimilar | Rx | CELLTRION, Inc. |
| 2023-06-01 | N | 002 | Yuflyma | 351(k) Biosimilar | Rx | CELLTRION, Inc. |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2025-05-01 | 001 | Yuflyma | 351(k) Interchangeable | Rx | Licensed | 2023-05-23 |
| 2025-05-01 | 002 | Yuflyma | 351(k) Interchangeable | Rx | Licensed | 2023-05-23 |
| 2025-05-01 | 003 | Yuflyma | 351(k) Interchangeable | Rx | Licensed | 2023-09-29 |
| 2025-04-01 | 004 | Yuflyma | 351(k) Interchangeable | Rx | Licensed | 2023-09-29 |
| 2025-04-01 | 005 | Yuflyma | 351(k) Interchangeable | Rx | Licensed | 2023-09-29 |
| 2023-10-01 | 003 | Yuflyma | 351(k) Biosimilar | Rx | Licensed | 2023-09-29 |
| 2023-10-01 | 004 | Yuflyma | 351(k) Biosimilar | Rx | Licensed | 2023-09-29 |
| 2023-10-01 | 005 | Yuflyma | 351(k) Biosimilar | Rx | Licensed | 2023-09-29 |
| 2023-06-01 | 001 | Yuflyma | 351(k) Biosimilar | Rx | Licensed | 2023-05-23 |
| 2023-06-01 | 002 | Yuflyma | 351(k) Biosimilar | Rx | Licensed | 2023-05-23 |